Vol. XXII · No. 04Spring 2026
TaihoTaiho Ventures

Letter from the Partners · No. 04

On Patient Capital, and the Difference Between a Term Sheet and a Time Horizon

The phrase has been worn smooth by use. We would like to argue that, in oncology, it still describes a real and operational thing.

By the Partners of Taiho Ventures

Strategic capital is a phrase that hides more than it explains. Used loosely, it means any investor who claims to add value beyond the wire. Used specifically, it means a small handful of corporate venture firms whose presence on a cap table changes what the molecule can become — by signaling, before the obvious buyers have looked, that someone with the infrastructure to license, co-develop, or acquire has already signed off on the science.

That second definition is rarer than the first, and worth more, because the work it implies is patient rather than transactional. A traditional fund prices a round, takes its seat, and spends the next eighteen months managing toward an exit. A strategic that is serious about the work — the kind that has its own R&D organization, its own clinical operations, its own commercial team in markets the founder may eventually want to enter — has a longer horizon and a different question. The question is not what the asset is worth at the next round. It is what the asset is worth at Phase II, and again at Phase III, and finally on a label.

In oncology that question is asked in years, not quarters. The molecule that closes a Series A in 2018 may not produce its first interim readout until 2023; the Phase III may not run until 2027. Patient capital, in this category, is not a marketing line. It is the operational requirement of the science.

I.

The Word Strategic

The word is doing work it cannot bear alone. Founders hear it from every fund they take a meeting with, and so it has come to mean both everything and nothing. Used loosely, it gestures at a Rolodex. Used specifically, it ought to mean an investor whose own balance sheet contains the resources the asset will eventually need, and whose institutional patience is calibrated to the timelines the science actually runs on.

Taiho Pharmaceutical has been in oncology for fifty years. It manufactures, registers, and commercializes its own medicines in Japan, the United States, and Europe. Its development organization runs Phase I through registration. Its commercial team has, for decades, fielded sales forces calling on the same oncologists a Series-A founder hopes to one day reach. None of this, by itself, makes a fund. What it makes is the apparatus inside which a fund can operate without flinching at a fifteen-year horizon. The fund is the index of that apparatus into a checkbook.

We mention this not as a credential but as an honest disclosure. The investors a founder should be most careful with are the ones whose patience exists only as a marketing claim. The investors a founder should be least afraid of are the ones whose patience is structural — who lose nothing by waiting because the parent organization has been waiting, in this category, longer than most funds have existed.

Patient capital, in this category, is not a marketing line. It is the operational requirement of the science.

II.

What the Cap Table Sees First

A cap table is read twice. The first reading is by the founder and the early team, who see it as a record of who said yes, in what order, at what price. The second reading happens later, sometimes years later, when a partner at a downstream firm or a corp-dev officer at a future acquirer pulls it up to understand what kind of company this is. The second reading is the more consequential one, and it is the one a founder rarely chooses for.

The presence of a serious strategic at the seed or A is an interpretive cue for that second reader. It says, before the science has been re-diligenced, that someone whose own organization runs the relevant chemistry — or the relevant indication, or the relevant geography — has looked at this molecule and chosen to put capital and reputation behind it. That cue is not a guarantee. It is, however, the difference between a downstream investor reading a cap table cold and one reading it with a thumb on the scale of prior conviction.

We have watched founders use this cue well, and we have watched it be wasted. Used well, it shortens diligence in the next round and widens the field of plausible acquirers. Wasted, it sits as a logo on a slide and signals nothing because the strategic was never asked to do anything for the asset other than be on the cap table. Our preference is for the first kind of relationship; the second kind is, we think, a quiet insult to the work.

A cap table is read twice. The second reading is the consequential one, and it is the one a founder rarely chooses for.
A hand annotating a printed Phase II readout with a pen, table light from above, paper visible at the edge of frame.
Figure 1A Phase II interim readout, annotated by a partner the morning of the call. The horizon between data and decision, in this category, is measured in years.

III.

Three Molecules

It is easier to argue all of this in the abstract than to defend it in the particular. The three vignettes that follow are particulars. Each is a portfolio company; each is at a different stage; each is the kind of work this fund exists for. We have set them, deliberately, as small captioned figures rather than as a feature grid — not because they are small companies, but because they are part of the argument and not separate from it.

A vial held to a window, ribbon of label visible, the rest of the lab out of focus.

Figure 2

TVL-031 — a FOXM1-targeted oncolytic

Phase Ib · solid tumors

The asset began as an academic series at a Boston lab whose principal investigator had spent a decade on a transcription factor most pharma had given up on. Our role at seed was modest in dollars and meaningful in everything else: chemistry guidance from inside Taiho, a co-development conversation that started during the round, and the time horizon needed to take a difficult target seriously.

A gloved hand placing a cassette into an automated cell-processing instrument, lit from the instrument display.

Figure 3

Cellbright Therapeutics — a TIL platform

IND-enabling · adoptive cell therapy

The platform asks a manufacturing question more than a discovery one — how to compress a six-week TIL expansion into a window the U.S. clinic can actually accommodate. We were the first institutional capital and the only investor at the round whose parent organization runs its own sterile fill-finish. The conversations between the Cellbright process team and the Taiho manufacturing group did not show up in a press release. They showed up in the protocol.

A founder and a Taiho partner walking down a hospital corridor, both reading from the same printed agenda.

Figure 4

Quivira Bio — a precision GI program

Phase II readout pending

A small Cambridge company with one Phase II asset and a question about commercialization in markets the founders had never sold into. Our partners flew, twice, to introduce the team to oncologists in Tokyo, Osaka, and Fukuoka — not to brokerage them as customers but to show the founders what the practice looks like in clinics they would otherwise have read about secondhand. The asset is the same asset. The understanding around it is not.

IV.

A Question Asked in Years

There is a kind of company we are not the right partner for, and it is worth being plain about it. A founder optimizing for a forty-month exit, with an asset whose value lives almost entirely in a near-term licensing deal, will be better served by a fund built for that arc. A founder optimizing for a label — for the eventual moment when an oncologist writes a prescription for a patient sitting in an exam room — is the founder we are built to serve. The two are not the same founder. They are not the same company. They are not the same risk.

We are aware that this is a quieter pitch than the one most founders are used to hearing. We are aware that strategic, said often enough, becomes a sound rather than a meaning. We are also aware that the molecules this country will be glad to have, in fifteen years, are being capitalized today by investors whose horizons are honest. We have written this letter to be one of them, in the public.